Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

Journal of Neurology

Volumn 244, Issue 3, 1997, Pages 153-159

  Millefiorini, E ^a   Gasperini, C ^a   Pozzilli, C ^a   D'Andrea, F ^b   Bastianello, S ^a   Trojano, M ^c   Morino, S ^a   Brescia Morra, V ^d   Bozzao, A ^b   Calo', A ^c   Bernini, M L ^d   Gambi, D ^e   Prencipe, M ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

Author keywords

Magnetic resonance imaging; Mitoxantrone; Multiple sclerosis

Indexed keywords

ALKYLATING AGENT; MITOXANTRONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS; PLACEBOS; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 8044242916     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150050066     Document Type: Article

References (34)

1. Bastianello S, Pozzilli C, D'Andrea F, et al (1994) A controlled trial of Mitoxantronc in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 21: 266-270
2. Benjamin R, Chawla SP, Ewer MS, et al (1985) Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update. Invest New Drugs 3: 117-121
3. Cook SD, Devereux C, Troiano R, et al (1986) Effect of total lymphoid irradia tion in chronic progressive multiple sclerosis. Lancet 1: 1405-1409
4. De Castro S, Cartoni D, Millefiorini E, et al (1995) Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting MS. J Clin Pharmacology. J Clin Pharmacol 35: 627-632
5. Edan G, et al (1995) Demonstration of the efficacy of mitoxantrone using MRI in MS patients with a very active disease. Neuroimmunology [Suppl 1]: 16
6. Faulds D, Balfour JA, Chrisp P, et al (1991) Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the chemotherapy of cancer. Drugs 41: 400-499
7. Fidler JM, Quinn De Joy S, Gibbonson JJ Jr (1986) Selective immunomodulation by the antineoplastic agent mitoxantrone. J Immunol 137: 727-732
8. Gonsette Re, Demonty L (1990) Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology 40 [Suppl 1]: 261
9. Hafler DA, Weiner HL (1989) MS: a CNS and systemic autoimmune disease. Immunol Today 10: 104-107
10. Henry WL, De Maria A, Gramiak R, et al (1980) Report of the American Society of Echocardiography Committee on nomenclature and standards in two-dimensional echocardiography. Circulation 62: 212
11. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655-661
12. Johnson KP, Brooks BR, Cohen JA, et al (1995) Copolymer 1 reduces exacerbation rate and improves disability in relapsing remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45: 1268-1276
13. Kappos L, Gold R, Kunstler E, et al (1990) Mitoxantrone (MX) in the treatment of rapidly progressive multiple sclerosis: a pilot study with serial gadolinium (GD)-enhanced MRI. Neurology 40 [Suppl 1]: 261
14. Killian JM, Bressler RB, Armstrong RM. et al (1988) Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Arch Neurol 45: 27-30
15. Krapf H, Mauch E, Fetzer U, et al (1995) Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology. 37: 113-119
16. Kurtzke JF (1983) Rating neurologicimpairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1442-1452
17. Landis JR, Kock GG (1977) Measurement for observer agreement for categorical data. Biometrics 33: 159-174
18. Likosky WH, Fireman B, Elmore R, et al (1991) Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry 54: 1055-1060
19. Lubin ED, Lavasa M, Viti C, et al (1987) Suppression of acute and relapsing exerimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol 45: 122-128
20. McDonald M, Posner LE, Dukart G, et al (1985) A review of the acute and chronic toxicity of mitoxantrone. Future Trends Chemother 6: 443-450
21. Noseworthy JH, Lee D, Penman M, et al (1991) A phase II evaluation of mitoxantrone HCL in the treatment of progressive MS. Neurology 41 [Suppl 1]: 146
22. Noseworthy JH, Hopkin MB, Vandervoort MK, et al (1993) An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 43: 1401-1406
23. Noseworthy JH, Ebers GC, Vandervoort MS, et al (1994) The impact of blinding on the result of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 44: 16-20
24. Paty D, Willoughby E, Whitaker J (1992) Assessing the outcome of experimental therapies in multiple sclerosis patients. In: Rudick RA, Goodking DE (eds) Treatment of multiple sclerosis. Trial design, results and future perspectives. Springer, Berlin Heidelberg New York, pp 47-90
25. Poser CM, Paty DW, Scheinberg L, et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227-231
26. Posner LE, Dukart G, Goldelberg J, et al (1985) Mitoxantrone: an overview of safety and toxicity. Invest New Drugs 3: 123-132
27. Rudge P, Koestier JC, Merlin J, et al (1989) Randomised double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiatry 52: 559-565
28. The Multiple Sclerosis Study Group (1990) Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Comments. Ann Neurol 27: 591-605
29. Villani F, Galinberti M, Crippa F (1989) Evaluation of ventricular function by echocardiography and radionuclide angiography in patients treated with mitoxantrone. Drugs Exp Clin Res 15: 501-506
30. Weiner HL, Mackin GA, Orav EJ, et al (1993) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis. Final report of the Northeast Cooperative multiple sclerosis treatment group. Neurology 43: 910-918
31. Weiss RB (1989) Mitoxantrone: its development and role in clinical practice. Oncology Huntingt 3: 135-141
32. Whitaker JN (1994) Rationale for immunotherapy in multiple sclerosis. Ann Neurol [Suppl] 36: s103-s107
33. Wiles CM, Omar L, Swan AV, et al (1994) Total lymphoid irradiation in multiple sclerosis. J Neurol Neurosurg Psychiatry 57: 154-163
34. Yudkin PL, Ellison GW, Ghezzi A, et al (1991) Overview of azathioprine treatment in multiple sclerosis. Lancet 338: 1051-1055